Why does pheochromocytoma cause weight loss and constipation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Why Pheochromocytoma Causes Weight Loss and Constipation

Pheochromocytoma causes weight loss through catecholamine-induced hypermetabolism that increases resting energy expenditure by approximately 10%, and causes constipation through excessive norepinephrine's inhibitory effects on intestinal motility via alpha-adrenergic receptor activation.

Mechanism of Weight Loss

The weight loss in pheochromocytoma results from chronic catecholamine excess creating a hypermetabolic state 1. Research demonstrates that patients with pheochromocytoma have resting energy expenditure (REE) that is 10.4% higher than predicted values (1731 vs 1581 kcal/day), despite normal food intake 2. This occurs because:

  • Norepinephrine and normetanephrine directly correlate with increased metabolic rate - these specific catecholamines show the strongest negative correlation with body weight 3
  • The chronic catecholamine overproduction induces a proinflammatory state with elevated TNF-α, IL-6, and IL-8, contributing to the hypermetabolic condition 2
  • After surgical removal, REE significantly decreases and patients typically gain weight, with body mass index increasing proportionally 2, 4

The weight loss is most pronounced in patients with high preoperative urinary normetanephrine levels 4. Persistently elevated catecholamines with decreasing weight indicate metastatic or recurrent disease 3.

Mechanism of Constipation

Constipation occurs in approximately 6% of pheochromocytoma patients and represents a potentially lethal complication 5. The pathophysiology involves:

  • Excessive norepinephrine inhibits intestinal motility through alpha-adrenergic receptor stimulation, causing intestinal pseudo-obstruction 6, 5
  • Constipation is specifically associated with excessive noradrenaline production (P<0.0001) 5
  • The condition typically occurs with large primary tumors (>5 cm) or extensive metastases 5

Clinical Significance and Management

Severe constipation can progress to toxic megacolon and sepsis, which has caused death in reported cases 5. The condition improves dramatically after tumor resection in non-metastatic cases 6, 5.

For symptomatic management before surgery:

  • Systematic combination of fiber, water, and laxatives effectively improves symptoms 5
  • Anti-cholinergic agents may benefit acute colonic pseudo-obstruction 7
  • Avoid dopamine antagonists (metoclopramide) and high-dose corticosteroids unless adequate alpha-blockade is established, as these can precipitate catecholaminergic crisis 7

Associated Clinical Features

Both weight loss and constipation typically occur alongside the classic triad of headaches, palpitations, and diaphoresis 1, 5. The presence of constipation as a presenting symptom should prompt evaluation for weight loss and excessive norepinephrine production, as these features cluster together 5.

Important caveat: Some patients present with atypical manifestations - constipation, intestinal pseudo-obstruction, and weight loss - without the typical hypertension or tachycardia 6. This can delay diagnosis, making it crucial to maintain clinical suspicion even when classic cardiovascular symptoms are absent.

References

Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

Research

Changes in energy metabolism in pheochromocytoma.

The Journal of clinical endocrinology and metabolism, 2013

Research

Changes in Body Mass Index in Pheochromocytoma Patients Following Adrenalectomy.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2017

Research

A case of pheochromocytoma associated with liver abscess and intestinal pseudo-obstruction.

Therapeutic advances in endocrinology and metabolism, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.